Printing And Publishing Tenders

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Golimumab (Atc Code According to Who: L04ab06)

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Infliximab (Atc Code According to Who: L04ab02), which is Used Subcutaneously. Applicants are Approved

Conclusion of Non-Exclusive Drug Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V by Means of a So-Called Oh Model for Ws Infliximab (Atc Code According to Who: L04ab02), which is Used Subcutaneously. Applicants are Approved

Collecting and transporting common household pollutants in the Rheinberg city area as well as transporting the collected pollutants to a disposal/recycling facility assigned by the Wesel district, if necessary also our own hazardous waste disposal fa

Renewal Of Fire Alarm System, Maintenance And Repair

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Leuprorelin, Atc L02ae02 for the Period December 1St, 2023 - November 30Th, 2024 (Plus Extension Option 1X12 Months)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate, Atc J05ar24 for the Period December 1St, 2023 - November 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Distigmin, Atc N07aa03 for the Period December 1St, 2023 - November 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Clobetasol, Atc D07ad01 for the Period December 1St, 2023 - November 30Th, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tocilizumab, Atc L04ac07 for the Period December 1St, 2023 - November 30Th, 2024 (Plus Extension Option 1X12 Months)